

# Investor Newsletter

Issue **10** 2015





## First Procedure of MicroPort® Orthopedics Firestone™ Cervical Fusion Device Successfully Completed

On October 19, Firestone™ Cervical Fusion Device ("Firestone™"), a product of Shanghai MicroPort Orthopedics Co ("MicroPort® Orthopedics"), had finished its first implantation procedure in Shijie Hospital of Dongguan City. The procedure was performed by Professor Dongming Guo, who is from Guangzhou First People Hospital, Spinal Surgery Department.

Applying Firestone™, the ACDF procedure was performed successfully and smoothly, taking only half an hour. The patient's immediate post-operative result was satisfied. The interbody fusion cage was developed and manufactured by MicroPort® Orthopedics independently from 2013 to 2015. With PEEK (polyetheretherketone) as the material, Firestone™ is indicated to primary stabilization for degenerative cervical intervertebral disc diseases, revision for previous cervical decompression with fixation.

After the procedure, Professor Guo gave a high recognition of both Firestone™'s high standard performance and MicroPort® Orthopedics team's service.

Firestone™ uses PEEK-OPTIMA polymer composites, has good biocompatibility and its elastic modulus is close to human bone. It can reduce the stress shielding effectively. It has the feature of permeable X-ray, which is convenient to postoperative observation of the bone fusion. The unique double-toothed structure of Firestone™ has the advantages of anti-slip and avoiding the displacement of the implant. The product received its CE certification of EU on 2013. This first successful implantation surgery marks the official entry of the product to the clinic, and will benefit more domestic patients.







## MicroPort® Attends TCT 2015

Shanghai MicroPort Medical (Group) Co ("MicroPort®") attended the 27th Transcatheter Cardiovascular Therapeutics ("TCT") in San Francisco from October 11 to October 15, to further promote its third-generation Drug Eluting Stent ("DES") Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®"). As the world's largest and most influential interventional cardiology conference, TCT attracted more than 13,000 industry professionals to participate this year.

In the session themed with "Metallic Drug-Eluting Stents: Tomorrow's Technology" on October 12, Professor Bo Xu from Fuwai Hospital, announced the long-term follow-up clinical study results of Firehawk® TARGET series, including the latest five-year clinical findings of TARGET FIM, the latest four-year clinical findings of TARGET I RCT and TARGET I long. The results of the three studies showed that the thrombosis incidence of Firehawk® was all 0%. The recurrence rate of myocardial infarction was 4.8%, 1.4% and 4.3% in these studies respectively. The target lesion revascularization rate driven by ischemia was 0%, 2.3% and 6.4%. The TARGET series clinical outcomes strongly proved the safety and efficacy of Firehawk® in the long-term clinical application.

During the meeting, Professor Xu further announced the design scheme of TARGET All Comer, Firehawk®'s post-market clinical trial in Europe. The trial is expected to be carried out in 20 sites across 10 European countries involving a total of 1656 patients. At present, the preparation of Firehawk® TARGET ALL Comer clinical trial has been completed, and the enrollment of the first patient will be carried out in Europe soon.

The 2nd Executive Committee Meeting of Firehawk® TARGET ALL Comer was held on October 13. The executive committee members include Professor William Wijns, President of EuroPCR and Primary Investigator of the trial, Professor Alexandra Lansky and Professor Andreas Baumbach, two Co-Primary Investigators respectively from Yale Cardiology and Bristol Heart Center and Professor Xu. The meeting focused on the trial progress, the final selection of sites, the treatment program of dual antiplatelet therapy and the latest European guidelines.

Amid the complex case sharing on October 14, Dr. Ferdinand Kiemeneij, the first physician using Firehawk® in Europe, shared his clinical experience of applying Firehawk® in treating complex lesions. The case was a CTO one with three Firehawk® stents implanted by using Chameleon technique. Dr. Kiemeneij was satisfied with the case results and also recognized Firehawk®'s excellent performance in treating complex lesions.



## MicroPort® Endovascular Castor™ Appearance 2015 International Endovascology Conference

From October 8 to October 10, the 2015 International Endovascology Conference was held in Shanghai. The conference was founded in 1997 and led by Professor Zaiping Jing from Changhai Hospital, who is China's famous vascular surgeon and who introduced the concept of "Endovascology". As the largest and highest level academic exchange platform in the field of vascular surgery and endovascular surgery in China, the topic of the conference covered multiple aspects including aortic dissection, aneurysm, lower extremity artery, carotid artery, internal organs and so on.

During the meeting, MicroPort Endovascular (Shanghai) Co ("MicroPort® Endovascular") held a Clinical Transformation Symposium for Castor Branched Aortic Stent Graft System ("Castor™"). Attended experts shared some excellent clinical performance of Castor™ before its releasing to the market.

On October 8, Castor™'s clinical transformation thematic discussion meeting was held successfully, which was organized by the Department of Vascular Surgery, Changhai Hospital of Second Military Medical University, with MicroPort® Endovascular being a co-organizer. The meeting invited 13 experts to give theme reports about Castor™'s clinical studies, shared the Castor™ excellent clinical performance, and released the one year clinical follow-up data summary of Castor™.


During the meeting, there was also a Castor™ clinical and translational signing ceremony. Bo Peng, Chief Marketing Officer of MicroPort®, Chairman of MicroPort® Endovascular, and Professor Jing of Changhai Hospital represented the two sides to sign a cooperation agreement, which marks the success of Castor™'s transformation--from scientific research to market.

Castor™ is the world's first branched stent graft system designed for a complete endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. Compared with other branch stent-grafts under development, Castor™ has less endoleak and better branch artery patency. It also features kink-free outer sheath, arch-passing ability, soft membrane as well as soft cap with branch stent cramped in.

In November 2014, Castor™ was selected as one of the projects of the National Key Technology R&D Program for China's 12th Five-Year Plan. The Castor™'s latest technology results of clinical research shows that under our independent research and development, with fully independent intellectual property rights, achieving internationally advanced level, the new endovascular graft has gradually become mature.



## The 125th Meeting of the Central Japan Association of Orthopaedic Surgery and Traumatology



From October 2 to October 3, MicroPort® Orthopedics Japan attended the 125th Meeting of the Central Japan Association of Orthopaedic Surgery and Traumatology at Nagoya, Japan.

Over 20 companies attended the congress, such as Zimmer Biomet, Stryker, Depuy Synthes and others. We had received 41 inquiries about our products.



## MicroPort® Orthopedics Life Style Solution of Hip and Knee Arthroplasty Conference

On September 17, Life Style Solution of Hip and Knee Arthroplasty Conference (the North American region) was held in Chicago, United States. Executive General Manager and Director of Marketing from MicroPort® Orthopedics and four surgeons attended the meeting.

The meeting was demonstrated and discussed from the aspects of rapid rehabilitation theory, surgical technique, implant material, biomechanical study and design principle of the prosthesis. During this meeting, the four Chinese surgeons communicated with surgeons from North America, and discussed the meaning of rapid rehabilitation for patients and hospitals in different regions.

After the meeting, the four surgeons visited the Hedley Orthopedic Medical Center, located in Phoenix, Arizona, and Boynton Beach, located in Miami, to observe the SuperPath™ operation. The trip of hospital visiting improved the academic exchanges, enhanced mutual understanding and helped promoting the SuperPath™ technique and minimally invasive concept in the development of the two countries.





## Preserve User-Group-Meeting in Germany



Germany held a very successful User-Group-Meeting about Preserve on Friday, October 2, 2015 in the nice region of Rhine River in Unkel. It was the first meeting of that kind but will not be the last one!

Surgeons from all regions in Germany came together to discuss about the Preserve Philosophy.

The faculty Dr. Rudolf Auen from Maria-Stern Hospital in Remagen and Professor Pavel Dufek from Klinikum Neustadt presented on the Preserve philosophy, outcome and patient satisfaction.

It was a very interactive meeting with experienced, new and interested Preserve surgeons.

The feedback from the attendees encouraged us to focus on these local meetings.

The next user-group-meeting is already planned during the DKOU-Congress in Berlin for October 22- but for AMP™!





## ISTA Congress Vienna, Austria

From September 30 to October 3, we were present at the 28th Annual ISTA Congress which took place in the Hilton Hotel in Vienna, Austria.

ISTA is a non-profit organization dedicated to advancing the art and science of joint replacement around the world. Every year they host a congress where the best clinicians, engineers, researchers, and industry members from across the globe come together to present and discuss leading edge work in the field of arthroplasty.

MicroPort® was present with a booth presenting our Medial Pivot philosophy as well as our SuperPath™ approach. Also, Dr. Chow presented an e-poster on his first 500 SuperPath™ THAs; Dr. Murphy had two e-posters and a presentation on SuperCap®.

Internally, our R&D and Clinical teams collaborated on two abstracts that were accepted as e-posters to support medial-pivot, both presented by A. Parker, Research Engineer, Applied Research.

The first discussed wear rates for eMP™ with conventional poly to be similar or lower than published rates for other systems with either conventional or cross-linked poly. The second was cadaveric data, showing quadriceps efficiency following TKA with medial-pivot is similar to non-operated controls.






## The 74th China International Medical Equipment Fair

From October 18 to October 21, the 74th China International Medical Equipment Fair (“CMEF”) was held in Wuhan, Hubei (Wuhan International Expo Center). We displayed MicroPort®'s new products as well as the full line of main products at this conference. The cardiovascular interventional products, large arteries and peripheral interventional products, medical equipment, surgical instruments, surgical instruments, nerve intervention products, electric physiology and medical devices were all presented at the same time.





## Jiangxi Province Big Blood Vessel Summit Forum

From September 18 to September 20, "Jiangxi Provincial Big Blood Vessel Summit Forum" was held in Nanchang. Several experts were invited to participate in the conference. A professor from the Second Xiangya Hospital of Central South University shared the classic case at the meeting on the "applying Castor™ in the clinical", leading a warm discussion. The southwest China sales staff of MicroPort® Endovascular also attended the meeting and exhibited Hercules™ Low Profile and Aegis™ Bifurcated Stent-Graft System. The excellent import performance and good bow compliance ability of Hercules™ Low Profile has been recognized by the experts.



## Meeting in Hulun Buir

On October 17, “the fourth seminar of the Hulun Buir Medical Association, vascular surgery branch” was held in Hulun Buir People's Hospital. The conference invited several experts from Beijing Friendship Hospital, the Affiliated Hospital of Inner Mongolia, Beijing Air Force General Hospital, China Japan Friendship Hospital, Beijing Jishuitan Hospital and so on to participate in. MicroPort® Endovascular North China Sales colleagues attended the meeting, and demonstrated MicroPort® Endovascular’s product—Castor™ in the field, which gained many advice.





## Regional meeting

From October 8 to October 10, "the Nineteenth Cardiovascular Disease Academic Conference" was held in Changzhou, Jiangsu. In addition to academic exchanges, the conference also invited famous experts to give special academic lectures to attendees. East China area sales staff of Shanghai MicroPort EP MedTech Co ("MicroPort® EP") attended the meeting, visited the experts and collected the feedbacks of product from customers.

## MicroPort EP Attends Industry Conference

From October 16 to October 18, "the 13th National Combined Chinese and Western Medicine Cardiovascular Disease Academic Conference" was held in Hefei, Anhui. The conference invited famous domestic experts to present special lectures to attendees. The Central China area sales staff of MicroPort® EP participated in the meeting, to make appointments with customers in the region, to collect information of products using in hospitals, and to develop new sales channels.





# Investor Newsletter

Issue **10** 2015



For more information, please contact:

**Hongbin Sun**

Chief Financial Officer

Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)

Tel: (86)(21) 38954600

Email: [ir@microport.com](mailto:ir@microport.com)